Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The second-line treatment in advanced NSCLC has been currently proved effective in prolonging
overall survival and improving quality of life. Both pemetrexed and erlotinib have been
approved for second-line treatment of NSCLC . Erlotinib is a valuable option for the
treatment of advanced NSCLC, especially for elderly patients, due to convenience of
administration and safety profile. The role of comprehensive geriatric assessment in
treatment efficacy and tolerance is an area of investigation.